Skip to main content

Pro00104564 Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

NCT04314089

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)

Associated Conditions

Lung Cancer

Principal Investigator

George Simon

Sponsor

Pro00104564 Duke Cancer Institute

You are being asked to take part in this research study because you have a recurrent, advanced stage of lung cancer (a type called non-small cell lung cancer or NSCLC), and there are no other standard therapies available. Research studies are voluntary and include only people who choose to take part. Please read this consent form carefully and take your time making your decision. As your study doctor or study staff discusses this consent form with you, please ask him/her to explain any words or information that you do not clearly understand. We encourage you to talk with your family and friends before you decide to take part in this research study. The nature of the study, risks, inconveniences, discomforts, and other important information about the study are listed below.

This study is currently enrolling.